[1] Shen YC,Chen CF,Chiou WF.Andrographolide prevents oxygen radical production by human neutrophils:possible mechanism(s) involved in its anti-inflammatory effect[J].Br J Pharmacol,2002,135(2):399-406. [2] Lee JC,Tseng CK,Young KC,et al.Andrographolide exerts anti-hepatitis C virus activity by up-regulating haeme oxygenase-1 via the p38 MAPK/Nrf2 pathway in human hepatoma cells[J].Br J Pharmacol,2014,171(1):237-252. [3] Jaruchotikamol A,Jarukamjorn K,Sirisangtrakul W,et al.Strong synergistic induction of CYP1A1 expression by andrographolide plus typical CYP1A inducers in mouse hepatocytes[J].Toxicol Appl Pharmacol,2007,224(2):156-162. [4] Li SG,Wang YY,Ye ZY,et al.Proliferative and apoptotic effects of andrographolide on the BGC-823 human gastric cancer cell line[J].Chin Med J,2013,126(19):3739-3744. [5] Bao GQ,Shen BY,Pan CP,et al.Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer[J].Toxicol Lett,2013,222(1):23-35. [6] Zhou J,Lu GD,Ong CS,et al.Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation[J].Mol Cancer Ther,2008,7(7):2170-2180. [7] Yuan H,Sun B,Gao F,et al.Synergistic anticancer effects of andrographolide and paclitaxel against A549 NSCLC cells[J].Pharm Biol,2016,54(11):2629-2635. [8] Mir H,Kapur N,Singh R,et al.Andrographolide inhibits prostate cancer by targeting cell cycle regulators,CXCR3 and CXCR7 chemokine receptors[J].Cell Cycle,2016,15(6):819-826. [9] 章倩倩,丁一,亓翠玲,等.穿心莲内酯对胶质瘤U87细胞增殖的抑制作用及其机制[J].吉林大学学报:医学版,2013,39(4):676-679. [10] Ferlay J,Soerjomataram I,Dikshit R,et al.Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136(5):E359-E386. [11] Coppin C,Porzsolt F,Autenrieth M,et al.WITHDRAWN:Immunotherapy for advanced renal cell cancer[J].Cochrane Database Syst Rev,2015(12):CD001425. [12] Escudier B,Eisen T,Stadler WM,et al.Sorafenib in advanced clear-cell renal-cell carcinoma[J].N Engl J Med,2007,356(2):125-134. [13] Escudier B,Eisen T,Stadler WM,et al.Sorafenib for treatment of renal cell carcinoma:Final efficacy and safety results of the phase Ⅲ treatment approaches in renal cancer global evaluation trial[J].J Clin Oncol,2009,27(20):3312-3318. [14] Rini BI,Wilding G,Hudes G,et al.Phase Ⅱ study of axitinib in sorafenib-refractory metastatic renal cell carcinoma[J].J Clin Oncol,2009,27(27):4462-4468. [15] Dai L,Wang G,Pan W.Andrographolide inhibits proliferation and metastasis of SGC7901 gastric cancer cells[J].Biomed Res Int,2017,2017:6242103. [16] Dai X,Zhang J,Arfuso F,et al.Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy[J].Exp Biol Med (Maywood),2015,240(6):760-773. [17] Amarante-Mendes GP,Griffith TS.Therapeutic applications of TRAIL receptor agonists in cancer and beyond[J].Pharmacol Ther,2015,155:117-131. [18] Elmallah MI,Micheau O.Marine drugs regulating apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)[J].Mar Drugs,2015,13(11):6884-6909. [19] 刘敏,赵苒.γH2AX检测在DNA双链断裂研究中应用[J].中国公共卫生,2015,31(6):742-746. [20] Lu C,Zhu F,Cho YY,et al.Cell apoptosis:Requirement of H2AX in DNA ladder formation,but not for the activation of Caspase-3[J].Mol Cell,2006,23(1):121-132. [21] 潘伟康,余辉,王怀杰,等.肾母细胞瘤中ERCC1、TUBB3、TOP2A mRNA的表达及临床意义[J].西安交通大学学报:医学版,2016,37(5):689-692. [22] 梁亮,张寅斌,张扬,等.miR-21在肾透明细胞癌中的表达及对增殖和凋亡的影响[J].西安交通大学学报:医学版,2017,38(6):826-832. |